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ORIGINAL ARTICLE
Drug susceptibility profile and pathogenicity of H7N9
influenza virus (Anhui1 lineage) with R292K substitution
Xiaonan Zhang1,*, Zhigang Song1,*, Jing He1,*, Hui-Ling Yen2,*, Jianhua Li3, Zhaoqin Zhu1, Di Tian1, Wei Wang1,
Lei Xu1, Wencai Guan1, Yi Liu1, Sen Wang1,3, Bisheng Shi1, Wanju Zhang1, Boyin Qin4, Jialin Cai4, Yanmin Wan5,
Chunhua Xu4, Xiaonan Ren4, Haili Chen1, Lu Liu5, Yuqin Yang4, Xiaohui Zhou4, Wenjiang Zhou4, Jianqing Xu3,5,
Xiaoyan Zhang3,5, Malik Peiris2, Yunwen Hu1 and Zhenghong Yuan3
Neuraminidase inhibitors (NAIs) are the only available licensed therapeutics against human H7N9 influenza virus infections. The
emergence of NAI-resistant variants of H7N9viruses with an NA R292K mutation poses a therapeutic challenge. A comprehensive
understanding of the susceptibility of these viruses to clinically available NAIs, non-NAIs and their combinations is crucial for effective
treatment. In this study, by using limited serial passage and plaque purification, an R292K variant of the Anhui1 lineage was isolated
from a patient with clinical evidence of resistance to oseltamivir. In vitro and cell-based assays confirmed a high level of resistance
conferred by the R292K mutation to oseltamivir carboxylate and a moderate level of resistance to zanamivir and peramivir. Non-NAI
antivirals, such as T-705, ribavirin and NT-300, efficiently inhibited both the variant and the wild-type in cell-based assays. A
combination of NAIs and non-NAIs did not exhibit a marked synergistic effect against the R292K variant. However, the combination of
two non-NAIs (T-705 and ribavirin) exhibited significant synergism against the mutant virus. In experimentally infected mice, the
variant showed delayed onset of symptoms, a reduced viral load and attenuated lethality compared with the wild-type. Our study
suggested non-NAIs should be tested clinically forH7N9patientswith a sustained high viral load. Possible drug combination regimens,
such as T-705 plus ribavirin, should be further tested in animal models. The pathogenicity and transmissibility of the R292K H7N9
variant should be further assessed with genetically well-characterized pairs of viruses and, most-desirably, with competitive fitness
experiments.
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INTRODUCTION
Anovel H7N9 avian influenza virus infecting humans in eastern China
was first reported on 30 March 2013.1 The epidemic curve of the first
wave of human infection spanned the period from mid-February to
the end ofMay 2013, and comprised 132 human infections with a case
fatality rate of 28%. The second wave of human infections from the
winter of 2013 to the spring of 2014 resulted in over 200 confirmed
cases.
Phylogenetic and evolutionary analyses of isolates from wild and
domestic birds collected from 2009 to 2013 suggested that the novel
avian H7N9 influenza virus arose from sequential reassortments in
domestic poultry involving distinct H9N2 donor viruses as well as
distinct H7 and N9 precursors in wild birds.2,3 Clinical isolates from
this epidemic were found to form two separate subclades. The domi-
nant genotype is that of the A/Anhui/1/2013 (Anhui1) lineage and the
minor one is represented by only two reported isolates: A/Shanghai/1/
2013 (Shanghai1)4 and A/Shanghai/05/2013(H7N9)5 (also reported as
A/Shanghai/JS01/2013(H7N9)6).
The initial sequence analysis of Shanghai1 revealed that its neura-
minidase (NA) protein has an R292K (N2 numbering) mutation,1
which has been reported to confer resistance to NA inhibitors
(NAIs).7,8 Further investigation indicated that the clinical isolate of
Shanghai1 was amixed population containing either arginine or lysine
at residue 292 of the NA. Plaque purification of clones containing
NAK292 confirmed its resistance phenotype against NAIs.9 We
and others reported that this mutation emerged in H7N9 patients
receiving NAI treatment.10,11 Furthermore, the emergence of the
R292Kmutation was accompanied by prolonged virus shedding and
adverse clinical outcomes in two patients.10 Of note, the viral isolates
obtained from these patients are of the Anhui1 lineage (data not
shown), which is distinct from the previously characterized
Shanghai1 virus with multiple amino-acid differences within the
receptor binding site of hemagglutinin (HA) (A138, V186 and L226
in Anhui1-like viruses, S138, G186 and Q226 in Shanghai1 virus).4,12
As the changes in the HA receptor binding domain may affect
the HA binding affinity or specificity, the above mentioned amino
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acid differences between Anhui1 and Shanghai1 may influence viral
dependence on NA activity and sensitivity to NAIs. Therefore, further
comprehensive analysis of the R292K mutant virus from this clinically
dominant Anhui1 subclade is necessary to further understand the
resistance spectrum, viral fitness and pathogenesis and to explore
possible therapeutic options for the control of this clinically challen-
ging variant. In the present study, we obtained an R292Kmutant virus
derived from an H7N9 (Anhui1 lineage)-infected patient in whom we
observed a sustained high viral load despite continued NAI treatment.
The mutant virus’s drug resistance profile and the pathogenesis of
infection in the mouse model were investigated in parallel with those
of its wild-type counterpart.
MATERIALS AND METHODS
Virus, compounds and reagents
All viruses were isolated and passaged in Madin–Darby canine kidney
(MDCK) cells (ATCC). A/Shanghai/2167/2010(H1N1) was isolated
from a patient infected with 2009 pdmH1N1 influenza virus. A/
Shanghai/5190/2013(H7N9) (denoted SH5190) was isolated from
patient number two described in our previous report, on day 8 post
NAI treatment.10 The patient started oseltamivir treatment (150 mg
twice daily) on day 6 post disease onset and switched to peramivir
(0.6 g once daily) on day 10 post disease onset (days 10–16). However,
persistent virus shedding was observed in serial nasopharyngeal sam-
ples despite continuous treatment with oseltamivir and peramivir. He
developed severe acute respiratory distress syndrome and died at day
19 after disease onset. An R292K mutation was later found in throat
swab samples starting from day 4 after oseltamivir treatment using
genotypic analysis. The R292K variant (SH5190 R292K) was derived
after serial passages and plaque purification. The genome sequences of
SH5190 R292K (KF997839-KF-997846) and SH5190 wild-type
(KF997831-KF997838) are available at NCBI. All experiments were
performed in a biosafety level 3 laboratory at the Shanghai Public
Health Clinical Center. Three clinically available NAIs were included
in our study: oseltamivir, peramivir and zanamivir. Oseltamivir car-
boxylate was provided by Hoffmann La-Roche (Basel, Switzerland).
Peramivir and zanamivir were purchased from Selleck Chemicals
(Housto, TX, USA). These compounds were dissolved in deionized water
and diluted for enzyme-based and cell-based assays. Three non-NAIs,
including favipiravir (T705), nitazoxanide (NT-300) and ribavirin, were
purchased from Sigma-Aldrich, Inc. (St Louis, MO, USA) and were
dissolved in DMSO. Exogenous bacterial neuraminidase derived from
Clostridium perfringens were purchased from Sigma-Aldrich, Inc.
Enzyme-based NA inhibition assay
The susceptibility of H7N9 viruses to oseltamivir carboxylate, zana-
mivir and peramivir was determined by the NA-StarTM Influenza
Neuraminidase Inhibitor Resistance Detection Kit (Applied Biosys-
tems, Foster City, CA, USA) according to the manufacturer’s instruc-
tions. The chemiluminescent signal was measured with a Victor 1420
multi-label counter (PerkinElmer, Waltham, MA, USA).
Plaque reduction assay
ConfluentMDCK cells in six-well plates were infected with SH5190 or
SH5190 R292K and diluted to 100 plague forming unit (PFU) per well
in dulbecco’s modified eagle medium (DMEM). After 1-h adsorption,
media were replaced with DMEM containing 1 mg/mL tosyl phenyla-
lanyl chloromethyl ketone (TPCK)-trypsin, 1% agarose and oseltami-
vir carboxylate at specified concentrations. Cells were subsequently
cultured for three days and the plaques were fixed in 10% neutral
formaldehyde overnight and stained with 0.5% crystal violet; plaque
diameters were measured. These experiments were repeated twice.
RNA extraction and quantitative real-time polymerase chain
reaction (qRT-PCR)
Viral RNAs were extracted using a QIAampViral RNAMini Kit (Qiagen,
Valencia, CA, USA) from a 140 mL volume specimen. Viral load was
measured by a TaqMan Real-time quantitative PCR assay using a one-
step RT-PCR kit (TaKaRa Bio, Shiga, Japan). A pair of in-house designed
primers and a probe (forward primer: 59-GAA GAG GCA ATG CAA
AAT AGA ATA CA-39, reverse primer: 59-CCC GAA GCT AAA CCA
RAG TAT CA-39 and probe: FAM59–CCA GTC AAA CTA AGC AGY
GGC TAC AAA-39BHQ) that specifically amplify a fragment of HA gene
influenza A subtype H7 virus were used. A TaqMan single nucleotide
polymorphisms (SNPs) assay for detecting the NA R292K oseltamivir-
resistance mutation was established,13 with primers (forward: 59-CAT
GTT ACG GGR ARC GAA CAG G-39, reverse: 59-TGG TCT ATT
TGA GCC CTG CC A-39), and probes (K292: FAM59-CAC ATG CAA
GGA CAA-39MGB; R292: VIC59-CAC ATG CAG GGA CAA-39MGB).
Virus yield reduction assay
The sensitivity of the wild-type and the R292K variant to NAIs and non-
NAIs were evaluated inMDCK cells against the following ranges of drugs:
oseltamivir carboxylate (0.03–100 mM for wild-type, 0.3–1000 mM
for mutant), peramivir (0.03–100 mM for wild-type, 0.3–1000 mM for
mutant), zanamivir (0.03–100 mM for wild-type, 0.23–500 mM for
mutant), ribavirin (0.03–100 mM), NT-300 (0.03–100 mM) and T705
(0.03–100 mM). Briefly, confluent cells in 96-well plates were inocu-
lated with SH5190 or SH5190 R292K diluted in DMEM (50 PFU/
well) at 37 6C for 1 h. The culture medium was then replaced with
DMEM containing 1 mg/mL TPCK-trypsin and antiviral compounds
diluted to various concentrations in triplicate. Supernatants were col-
lected 24 h post infection and influenza HA gene copy numbers were
quantified using one-step qRT-PCR. In some experiments, superna-
tants were collected 48 h post infection and were titrated in MDCK
cells to determine viral titers (log10 TCID50/mL). These experiments
were repeated at least twice. The 50% inhibitory concentration (IC50)
value of each drug was estimated using non-linear regression func-
tionality in GraphPad 5.0 with a variable slope and least-square fit
method. The 95% confidence interval of IC50 value was obtained after
nonlinear regression to reflect the reliability of the estimate.
Viral replication kinetics
Confluent MDCK cells in six well plates were infected with SH5190 or
SH5190 R292K at anmultiplicity of infection (MOI) of 0.001 PFU per
cell. Supernatants were collected at 0, 6, 12, 24, 36, 48 and 72 h post
infection. Viral titers (log10 TCID50/mL) in the supernatants were
determined by a 50% tissue culture infective dose (TCID50) assay.
The positivity of each well was determined by a hemagglutination
assay using guinea pig red blood cells.
Analysis of drug synergism
MDCKcells were infected with SH5190 R292K or SH5190 at an MOI
of 0.001 and were overlaid with medium containing oseltamivir car-
boxylate, zanamivir, peramivir, T705, ribavirin and NT-300 alone or
in combination (as indicated) at fixed molar ratios (for SH5190
R292K: T-705/zanamivir51 : 3, ribavirin/zanamivi51 : 4, NT-300/
zanamivir51 : 20, T-705/peramivir51 : 9, ribavirin/peramivir51 : 9,
NT-300/peramivir51 : 60, NT-300/ribavirin51 : 5, T705/ribavirin5
4 : 5, T-705/NT-30054 : 1; for SH5190 wild-type:/T-705/OC525 : 3,
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ribavirin/OC59 : 1, NT-300/OC51 : 3, T-705/zanamivir525 : 4,
ribavirin/zanamivir527 : 4, NT-300/zanamivir51 : 4, T-705/pera-
mivir5250 : 6, ribavirin/peramivir5270 : 6, NT-300/peramivir5
5 : 3, NT-300/Ribavirin51 : 27, T705/Ribavirin525 : 27, T-705/NT-
300525 : 1). Supernatants were collected 24 h post infection and viral
HA gene copy numbers were quantified using qRT-PCR. The com-
bination index (CI) was calculated by the Chou–Talalay method.14
The Chou-Talalay method ‘is based on the median-effect equation,
derived from themass-action law principle, which is the unified theory
that provides the common link between single entity and multiple
entities, and first order and higher order dynamics’.15 This method
recommends the constant-ratio drug combinations (at the (IC50)1/
(IC50)2) based on the notion that the mixture can be deemed as a third
drug. The dose–response curve and accompanying parameters for the
mixture can therefore be obtained. For a certain response rate, the CI
value is ((D)1/(Dx)1)1((D)2/(Dx)2), where Dx is for the drug alone
that inhibits a system x% and (D)11(D)2 in combination also inhibit
x%. A CI of ,1 indicates synergism (CI values are interpreted as
follows: ,0.1, very strong synergism; 0.1–0.3, strong synergism; 0.3–
0.7, synergism; 0.7–0.85, moderate synergism; and 0.85–0.90, slight
synergism). A CI of 1, or close to 1, indicates additive effects, and a CI
of .1 indicates antagonism.
Pathogenicity in the mouse model
Six- to eight-week-old female C57BL/6 mice were purchased from
B&K Universal Group (Shanghai, China) and were housed under
specific pathogen free conditions at the animal facility of the
Shanghai Public Health Clinical Center, Fudan University. Mice
(n516–18) were inoculated intranasally with 103 or 105 PFU of
SH5190 or SH5190 R292K in 50 mL phosphate buffered saline (PBS)
under isoflurane anesthesia. Their body weight, clinical signs and
survival were measured daily for 15 days. In compliance with animal
ethics, mice with weight loss over 30% or with an obvious dying
condition were euthanized. The survival experiments were repeated
twice. Threemice in each group were sacrificed at days 3, 8 and 11 post
infection and their lungs, livers, hearts and brains were collected for
viral titration. The right or left lung lobes were mechanically homo-
genized in sterile PBS and stored in 280 6C until use. Lung tissues
collected at day 8 post infection were fixed in 4% paraformaldehyde,
dehydrated, embedded in paraffin and cut into 5-mm-thick sections,
which were stained with hematoxylin and eosin. The slides were
viewed using an Olympus BX51 microscope, and the images were
captured and analyzed by the corresponding acquisition software
(DP controller; Olympus, Tokyo, Japan). All mouse experimental
procedures were approved by the animal ethics committee of the
Shanghai Public Health Clinical Center.
Statistical analysis
All statistical analyses were performed using GraphPad Prism 5.0
(Graphpad, La Jolla, CA, USA). The Mann–Whitney U test was used to
compare viral titers and animal weight loss. Themortality rates of different
virus challenge groups were assessed by the Kaplan–Meier method.
RESULTS
Isolation of oseltamivir-resistant H7N9 clinical variant of the
Anhui1 lineage
In a previous report, we identified the rapid emergence of oseltamivir
resistant variants in two severe cases of H7N9 influenza infection.
Sustained viral shedding was accompanied by the rapid emergence
of the NA R292K quasispecies.10 A virus isolate, A/Shanghai/5190/
2013(H7N9) (denoted SH5190), was cultured from nasopharyngeal
specimens collected on day 8 post NAI treatment frompatient number
two as reported previously, an 88-year-old male who died of H7N9
influenza-induced acute respiratory distress syndrome and multiple
organ failure. The presence of the R292K mutant was identified in the
mixed population at a proportion of 77%, by Taqman SNP assay (data
not shown). However, after one blind passage of the nasopharyngeal
specimen inMDCK cells, Taqman SNP analysis showed that the wild-
type 292R became dominant (100%). We hypothesized that the low
NA activity possessed by the R292K variant might render the mutant
strain less competent at competing with the wild-type virus. To isolate
the R292K variant, limited serial passages in the presence of an ascend-
ing concentration of oseltamivir carboxylate (from 10 mMto 500 mM)
and exogenous neuraminidase (2 mU/mL) were performed. The
R292K variant was successfully isolated under these conditions.
We then performed plaque purification to isolate individual clones
from the isolate. Fourmutant clones were selected and the full genome
was analyzed by Sanger sequencing. Among them, clone 27 had no
additional mutations other thanNAR292K andHAR220G (H3 num-
bering) (data not shown). No additional mutations in all eight gene
segments were observed (data not shown). Moreover, we did not
observe any reversion of the R292K mutation to wild-type 292R in
the absence of oseltamivir or exogenousNAduring subsequent experi-
ments, as evidenced by both Sanger sequencing and Taqman SNP
qPCR assay. This result suggested that the R292K mutation can be
stably maintained in cell culture. Thus, clone 27 (named SH5190
R292K) exhibited minimum adaptive mutation and was chosen in
conjunction with SH5190 for further study.
Replication of the SH5190 wild-type and mutant viruses in MDCK
cells
We first compared the proliferative property of SH5190 and the
R292K variant in cell culture. As shown in Figure 1, SH5190 R292K
replicated to comparable titers as the wild-type counterpart in multi-
cycle replication conditions in MDCK cells. The titers of the SH5190
R292K were even higher than those of the wild-type SH5190 at 12 h
(P,0.05). The plaque morphology showed no significant difference
between the mutant and the wild-type in the absence of oseltamivir
carboxylate (Figure 2). We thus concluded that the R292K mutant
virus can propagate efficiently in cell culture.
Sensitivity of SH5190 and SH5190 R292K to oseltamivir carboxylate
in plaque reduction assay
The significant difference in oseltamivir sensitivity between SH5190
and SH5190 R292K was first confirmed by a plaque reduction assay
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Figure 1 Replication kinetics of the wild-type virus and the R292K variant in
MDCK cells. Confluent MDCK cells were infected with an MOI of 0.001 PFU per
cell. Supernatants were collected at the time points indicated and titrated in MDCK
cells using a TCID50 assay. Each data point represents the log10 mean6
SEM TCID50/mL from three replicated wells. The experiments were repeated twice.
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under increasing concentration of oseltamivir carboxylate. As shown
in Figure 2, the plaque size of the SH5190 was significantly reduced in
the presence of 10 mM oseltamivir carboxylate (mean diameter
,0.1 mm) when compared to the no drug control (mean diame-
ter51.5 mm). In contrast, the plaque size of SH5190 R292K was not
significantly affected in the presence (mean diameter51.8 mm) or
absence (mean diameter51.8 mm) of 10mM oseltamivir carboxylate.
Only at 100 mM (mean diameter51.0 mm) or 1000 mM (mean dia-
meter50.8 mm) of oseltamivir carboxylate was there notable plaque
size reduction for SH5190 R292K, which indicated the highly resistant
phenotype to oseltamivir.
Sensitivity of SH5190 and SH5190 R292K to NAIs in enzyme
inhibition assay
The sensitivity of the SH5190 and SH5190 R292K to NAIs was further
confirmed using enzymatic methods. The NA-Star assay was applied
to determine the IC50 of NA enzymatic activity of SH5190 and SH5190
R292K in the presence of three clinically available NAIs: oseltamivir
carboxylate, zanamivir and peramivir. A 2009pdmH1N1 virus isolate
A/Shanghai/2167/2009 (denoted 2167) was included as a control. As
shown in Table 1 and Figure 3, the wild-type virus is highly susceptible
to all three NAIs, with IC50 values of 0.28 nM (peramivir), 0.48 nM
(oseltamivir carboxylate) to 0.74 nM (zanamivir). However, SH5190
R292K exhibited a highly reduced susceptibility to oseltamivir carbox-
ylate (IC50.1000 nM), which was out of the range of drug concentra-
tions used for the assay. Its sensitivities to zanamivir (IC50: 12.4 nM,
16.7-fold change) and peramivir (IC50: 96.5 nM, 344-fold change)
were also significantly reduced.
Sensitivity of SH5190 and SH5190 R292K to NAIs and non-NAIs in
virus yield reduction assay
Next, we analyzed the sensitivity of SH5190 and SH5190 R292K
against available NAIs and non-NAIs in a cell-based virus yield
reduction assay. As expected, oseltamivir carboxylate exhibited a poor
inhibitory effect against SH5190 R292K (IC50.1000 mM, Figure 4 and
Table 2). Zanamivir and peramivir moderately inhibited viral growth
with IC50 values of 33.5 mMand 898 mM, respectively. In contrast, the
wild-type virus is fully susceptible to all three NAIs with IC50 at sub-
micromolar values (oseltamivir carboxylate 0.37 mM, zanamivir
0.51 mM, peramivir 0.07 mM). Considering the adverse clinical out-
come associated with the emergence of the NA R292K mutation after
receiving NAI treatment, there is a pressing need to evaluate alterna-
tive therapeutic options to control this mutant virus. To this end, we
performed a cell-based assay to evaluate the inhibition of virus rep-
lication by three non-NAIs, T-705 (favipiravir), ribavirin and NT-300
(nitazoxanide), on the wild-type and the R292Kmutant. We observed
that SH5190 and the R292K mutant exhibited comparable sensitivity
to T-705 (IC50 values of 3.10 mM and 6.26 mM, respectively) and
ribavirin (IC50 values of 3.32 mM and 7.43 mM, respectively). NT-
300 was found to be over 25 times more potent than T-705 and riba-
virin, with IC50 values of 0.12 mM to the wild-type (Figure 3 and
Table 2). However, a greater than one log increase of IC50 in
SH5190 R292K was observed for NT-300 (IC50 values of 1.60 mM).
Evaluation of drug combinations on the R292K mutant virus
Combination therapy with drugs targeting different viral proteinsmay
reduce the emergence of drug-resistant mutants and may show syn-
ergistic inhibitory effects. For this consideration, we further investi-
gated if the combinations of non-NAIs (T705, ribavirin or NT-300)
with zanamivir or peramivir, which retained partial inhibitory activity
against the R292Kmutant virus, and combination between non-NAIs,
may act synergistically to suppress growth of the R292K variant. We
adopted the method of Chou and Talalay14 and computed the CI
based on the data from cell-based experiments. For comparison, drug
combinations were also tested on the wild-type virus. As shown in
Supplementary Table S1, we observed six pairs of drug combinations
(ribavirin1zanamivir; T-7051zanamivir; NT-3001peramivir; riba-
virin1peramivir; T-7051peramivir and NT-3001ribavirin) that can
achieve synergism at both IC50 and 90% inhibitory concentration
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Figure 2 Plaquemorphology of thewild-type (SH5190) and theR292K variant (SH5190R292K) in the absence or presence of oseltamivir carboxylate (10–1000 mM).
Table 1 IC50 value of the neuraminidase inhibitor in NA-star assay
IC50 value (nM) [mean (95% CI)]
Oseltamivir carboxylate Zanamivir Peramivir
SH5190 0.48 (0.42–0.54) 0.74 (0.59–0.94) 0.28 (0.25–0.30)
SH5190 R292K .1000 12.4 (9.67–15.9) 96.5 (10.2–91.1)
2167 1.96 (0.16–2.34) 0.18 (0.13–0.24) 0.11 (0.11–0.12)
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(IC90). For the R292K mutant, however, all combinations among NAIs
and non-NAIs exhibited antagonism largely or merely additive effects at
IC50 (Table 3), which may be because the mutant virus is partially res-
istant to both zanamivir and peramivir. A marginal synergistic effect can
only be observed at IC90s in three combinations (T7051zanamivir
CI50.717, NT-3001peramivir CI50.700, ribavirin1peramivir
CI50.444). For combinations of non-NAIs, moderate synergism was
observed for NT-3001Ribavirin at IC50 (CI50.852). Of note, consistent
synergism at IC50 and IC90 was only observed in the combination of T-
705 and ribavirin (CI at IC5050.732, CI at IC9050.578; Table 3).
Pathogenesisof R292K mutant virus in experimentally infected
mice
To gain a better understanding of the pathogenesis of the wild-type
and mutant H7N9 virus in vivo, C57BL/6 mice were intranasally
inoculated with either SH5190 or SH5190 R292K at 105 PFU (high
dose group) or 103 PFU (low dose group) and were monitored for 15
days. As reported previously, C57BL/6 mice infected with the H7N9
virus developed ruffled fur and difficulty in breathing, decreased their
food and water intake and had obvious weight loss.16 However, the
wild-type and the R292K variant showed an apparent difference in
virus induced morbidity. As shown in Figure 5A, SH5190 R292K-
infected mice exhibited a significant delay in weight loss compared
to mice infected with the wild-type strain (Figure 5A). The difference
between the wild-type and the R292K mutant was best exemplified at
day 5 after infection in the high (P,0.0001, Mann–Whitney U test)
dose group. Viral loads in mouse lungs were quantified using one-step
qRT-PCR with RNA derived from homogenizedmouse lungs collected
at days 3, 8 and 11 post inoculation. The R292K variant was observed
to replicate less efficiently than the wild-type at day 3 post inoculation
(2.32 versus 3.49 log10copy/mg RNA, P50.05, Mann–Whitney U test).
However, the viral loads of the two viruses were not significantly
different at days 8 and 11 post infection (Figure 5B). The difference
between SH5190 and SH5190 R292K in mouse lung titers is consistent
with the trend in weight loss (Figure 5A) and the lethality of the viruses
in mice (Figure 5C). Mice inoculated with a high dose of the wild-type
virus resulted in a 45.5% (5/11) survival, whereas 90.9% (10/11) of the
mice survived after infection with the same dose of the R292K variant
after 15 days of observation (P50.018) (Figure 5C).
Hematoxylin and eosin staining of lung tissues collected 8 days post
infection also exhibited a different degree of pulmonary damage and
inflammation. In SH5190 R292K-infected lungs, the alveolar septum
was slightly thickened with the infiltration of inflammatory cells. The
alveolar space was diminished and the serosity and inflammatory cell
exudation were observed only in part of the pulmonary alveoli
(Figures 6A and 6B). In comparison, eight days after SH5190 infection
already resulted in diffused serosity and inflammatory cell (mono-
cytes, macrophages and lymphocytes) exudation in most alveoli
(Figures 6C and 6D), which seriously compromised the gas exchange
efficiency. Of note, we did not detect a reversion of the R292K muta-
tion back to the wild-type in the lungs of mice inoculated with SH5190
R292K during the observation period; in parallel, no R292K mutation
was found in mice inoculated with the wild-type virus, as evidenced by
the SNP qPCR assay (data not shown).
DISCUSSION
In contrast to previous zoonotic H7 influenza infections that rarely
caused lethal infections in humans, the novel H7N9 avian influenza
virus first reported in eastern China in March 2013 can cause severe
pneumonia and acute respiratory distress syndrome) with a case fa-
tality rate over 28%.1,17 It is disturbing that H7N9 infections may not
always be effectively treated with oseltamivir, even when treatment is
started early because of the emergence of resistant variants that lead to
adverse clinical outcomes.10,18 We recently reported the emergence of
the R292Kmutation in theNA segment in twoH7N9 fatal cases during
NAI treatment.10 Thus, it is of clinical and scientific importance to
characterize R292K variants of the dominant Anhui1 lineage (the
dominant H7N9 virus lineage) from clinical specimens. Previous
reports have generated a drug-resistant virus by introducing a
Shanghai1 NA segment with a 292K mutation into a Anhui1 gene
frame using reverse genetics.19 To make an NAI-resistant strain, we
report here the isolation of the R292K mutant virus of Anhui1 lineage
without genetic manipulation. This R292K variant derived from a
clinical specimen is critical to confirm the results derived from recom-
binant viruses and to investigate potential antiviral strategies to inhibit
the NAIs-resistant strain.
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Figure 3 Dose–response curve of the SH5190, SH5190 R292K and the
A(H1N1)pdm09 (2167) viruses in the presence of oseltamivir carboxylate (A),
zanamivir (B) and peramivir (C) using a chemiluminescent (NA-star) assay. The
NA activity of the H7N9 or H1N1 viruses under increasing concentrations (0.03–
1000 nM) of the NAIs was determined. Each data point represents the normal-
izedmean6 SEM neuraminidase activity from three replicated wells. The experi-
ments were repeated twice.
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Interestingly, we had difficulty isolating the R292K variant in vitro
under oseltamivir carboxylate selection pressure alone (data not
shown). The addition of exogenous NA from Clostridium perfringens
greatly facilitated this process, possibly because of the low NA activity
exhibited by the R292K variants.9,20 Nevertheless, the R292K variant
that we obtained through plaque purification efficiently replicated in
MDCK cells when exogenous NA was withdrawn (Figures 1 and 2).
We speculate that the R292K mutation caused subtle changes in the
activity of neuraminidase, which may need some compensatory inter-
mediate mutations in the NA and/or HA segment. The exogenous NA
fromClostridium perfringensmight facilitate this process. Full genome
sequencing showed that in addition to the R292K mutation in the NA
gene, this variant as only one amino acid substitution (R220G) in the
proximity of the HA receptor binding domain. It is possible that the
mutations in the HA gene, such as R220G, may achieve a balance
between the HA and NA protein in the NAI resistant virus. The exact
mechanism of this phenomenon would require further investigation.
The R292K mutant virus exhibited a high level of resistance to
oseltamivir with the IC50-fold change .1000, but the replication of
the variant can be partially inhibited under a high concentration of
zanamivir or peramivir, a finding similar to previous reports.9,20–22
Among available NA inhibitors, zanamivir showed the best inhibitory
effect against the R292K variant with the lowest IC50 value in enzyme-
based or cell-based assays.However, inhaled zanamivir is currently not
recommended for H7N9 patients who may have impaired lung func-
tion and there are not sufficient data regarding the use of inhaled
zanamivir in patients with severe influenza disease. Whether intraven-
ous zanamivir could control an oseltamivir-resistant virus should be
further tested in animal models and clinical investigations.
Notably, non-NAIs, including inhibitors for viral polymerase acti-
vity (ribavirin and T705), largely retained their effectiveness against
the R292K variant. However, forNT-300, known as an inhibitor toHA
glycoproteinmaturation, an over 10-fold increase of IC50 to the R292K
variant is speculated to be caused by anHAR220Gmutation, although
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Figure 4 The sensitivity of the wild-type and the R292K virus to oseltamivir carboxylate, zanamivir, peramivir, T705, ribavirin and NT-300 in MDCK cells. MDCK cells
were infected with the wild-type or R292K variant at a dose of 50 PFU/well and were incubated at 37 6C for 1 h, after which the inoculum was removed. Antiviral
compounds were diluted to specified concentrations, added in the culture and incubated at 37 6C. Supernatants were collected 24 h post infection and viral loads
under different antiviral compoundswere quantified using qRT-PCR to determine the influenzaA virusHAgene copy numbers. Each data point represents themean6
SEM of log10 copy number from three replicated wells. The experiments were repeated at least three times.
Table 2 Cell culture-based IC50 values of NAIs and non-NAIs
IC50 value (mM) [mean (95% CI)]
Oseltamivir carboxylate Zanamivir Peramivir T-705 Ribavirin NT-300
SH5190 0.37 (0.30–0.47) 0.51 (0.31–0.83) 0.07 (0.05–0.10) 3.10 (1.67–5.76) 3.32 (1.61–6.83) 0.12 (0.07–0.21)
SH5190 R292K .1000 33.5 (7.35–152.6) 898 (N.A.) 6.26 (4.96–7.90) 7.43 (7.80–9.52) 1.60 (1.14–2.23)
Abbreviation: N.A., not available.
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no experimental evidence is available. Further mouse studies should
be performed to determine whether these non-NAIs could be effective
against H7N9 viruses even when administered post infection because
antiviral treatment is often delayed in infected patients.
Although significant synergism is found against the wild-type
virus by combining zanamivir/peramivir and non-NAIs, these regi-
mens generally did not exhibit a synergistic effect against the R292K
virus. We suspect that the high resistance of the R292K virus
against NAIs greatly attenuated the synergism of combining
zanamivir/peramivir and non-NAIs especially at median IC50.
Importantly, we observed that T-7051ribavirin constituted a mod-
erate synergistic pair that cooperatively restricted viral growth in
the cell culture model. Further animal experiments are needed to
further corroborate its therapeutic advantage by utilizing the
scheme designed by Chou14 for assessing drug synergism in vivo.
Apart from its drug sensitivity profile, the in vivo fitness of the
R292K mutant virus is also of scientific importance. A number of
publications have addressed this issue using various viral isolates or
recombinant viruses in different animal models.19,21–23 The main
findings were summarized in Table 4. Watanabe et al.19 generated a
recombinant Anhui1 virus containing a Shanghai1 NA segment.
Although not explicitly stated, the engineered mutant virus exhi-
bited a lower titer in infected mouse lung than its wild-type counter-
part at both 103 and 104 PFU dosages. Alleviated weight loss was also
observed after infection with a mutant virus (104 PFU inoculation).
However, recombinant Shanghai1 (292K) and Shanghai1 with Anhui1
NA (292R) generated by Rong et al.21 showed comparable virulence in
mice and aerosol transmission rate in guinea pigs. Marjuki et al.22
observed similar results using either Shanghai1 wild-type and
R292K or Taiwan1 wild-type and R292K viruses. However, they
found the HA of the Shanghai1R292K virus had a mixture of
151A/S and 209G/E (2013 H7 numbering), while that of the
Taiwan1 mutant virus possesses a D340G substitution. Lastly, in
an attempt to evaluate the pathogenicity and transmission potential
of the R292K variant in a model closest to human infection, the
Shanghai1 MUT-6 virus, which had 94% of 292K and 6% of 292R,
was inoculated in ferrets and transmitted via direct and respiratory
droplet contact. Quantitative analysis of the wild-type and the
R292K variant during the course of transmission revealed that,
although the R292K mutant had transmission potential, the mutant
virus was outcompeted by the wild-type in the upper respiratory
tract of inoculated donors and transmitted ferrets, which was sug-
gestive of a competitive fitness loss.23
In the current study, we observed that, although both viruses exhib-
ited similar growth kinetics in MDCK cells, mice inoculated with the
R292K variant showed delayed weight loss, lower viral loads in the lung
at day 3 post inoculation, milder pathological changes and greater
survival rates. A number of factors may cause this discrepancy, including
binding avidity to a-2,3-linked and a-2,6-linked sialic acid, cell tropism
and adaptation, innate and adaptive immune response in mice. The
compromised pathogenicity in vivo is attributed to the combined NA
R292K and HA R220G mutations. It is possible that the reduced NA
activity caused by the R292K mutation is responsible for the reduced
fitness. However, the R220Gmutation, which resides in the proximity of
the HA receptor binding domain, might also contribute to compro-
mised fitness in mice. Further study is needed to clarify the role of the
HA R220G mutation on receptor binding activity and in vivo fitness.
The lack of concordance on the in vivo fitness of the R292K variant
is reminiscent of the literature on the fitness of the H274Y mutation
in 2009 H1N1 pandemic viruses.24 Indeed, the viral strains and
Table 3 Combination Index for selected NAIs and non-NAIs against
R292K-resistant H7N9 virus
Drug A Drug B CI at IC50 CI at IC90
NT-300 Zanamivir 3.253 1.484
Ribavirin 4.553 3.552
T-705 2.115 0.717
NT-300 Peramivir 2.700 0.700
Ribavirin 1.266 0.444
T-705 2.050 3.708
NT-300 Ribavirin 0.875 1.611
T-705 Ribavirin 0.732 0.578
T-705 NT-300 1.067 1.055
CI values that are less than 1 are in boldface.
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Figure 5 Pathogenicity of the H7N9 wild-type and the R292K variant in the mouse
model. C57BL/6 mice (n511 per group) were infected with 105 (high dose) or 103
(low dose) PFU of either the wild-type virus or the R292K variant. Themean6 SEMof
mouse weight changes (%) were recorded daily for 15 days (A); viral loads (influenza
A virus HA gene copy numbers) in mouse lungs collected on days 3, 8 and 11 post
infection in high-dose groups were quantified using real-time one-step qRT-PCR and
expressed as mean 6 SEM of log10 copy number. (B); mouse survivals after inocu-
lation with the wild-type or the R292K variant at different doses were recorded and
plotted (C). N.D. not detectable. These experiments were performed twice.
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experimental conditions have a profound influence on the results. For
H7N9 viruses, the use of Shanghai1 or Anhui1-like viruses, which differ
by seven amino acids in the HA segment, can cause a significant differ-
ence. In addition, mutations other than NA 292, which may cause a
compensatory effect, could also significantly affect the final readout.
Taken together, we report here the isolation and characterization of
the R292K variant from a clinical specimen derived from an H7N9
fatal case of the Anhui1 lineage. It has highly reduced susceptibility to
oseltamivir and reduced susceptibility to zanamivir/peramivir, but
largely retained sensitivity to non-NAIs (favipiravir, nitazoxanide
and ribavirin). The combination of favipiravir and ribavirin may
synergistically restrict the spread of the R292K variant and needs to
be tested in animal models. The reduced pathogenicity of the R292K
variant suggests that it is partially compromised in vivo, at least in the
mouse model. The in vivo fitness of the R292K H7N9 variant virus
should be further assessed with genetically well-characterized pairs of
viruses and most desirably, with competitive fitness experiments.
Resistant variants should be closely monitored, both genotypically
and phenotypically, in H7N9 patients under NAI treatment.
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